Develops first-in-class oncology therapeutics targeting the Wiskott–Aldrich Syndrome Protein (WASP) to inhibit cancer progression.
BIMINI Biotech
Details
- LSH Companies
Langegracht 70, 2312 NV, Leiden
Develops first-in-class oncology therapeutics targeting the Wiskott–Aldrich Syndrome Protein (WASP) to inhibit cancer progression.
Langegracht 70, 2312 NV, Leiden